AACR Special Conference – Pancreatic Cancer: Progress and Challenges

Home Research Strategic Research Program Pancreatic Cancer News AACR Special Conference – Pancreatic Cancer: Progress and Challenges

Research in the News

AACR Special Conference – Pancreatic Cancer: Progress and Challenges

For the first time, the American Association for Cancer Research (AACR) will offer a special conference completely devoted to pancreatic cancer. The meeting will take place June 18-21, 2012, at the Hyatt Regency in Lake Tahoe, NV. Scientists at all career levels will attend, share ideas, and have the opportunity to engage with world leaders in the field. The Pancreatic Cancer Action Network is proudly serving as the lead supporter of this meeting.

Co-chairs of the conference include Dafna Bar-Sagi, PhD and Dave Tuveson, MD, PhD. Both Drs. Bar-Sagi and Tuveson are past recipients of Pancreatic Cancer Action Network research grants, and have both been dedicated members and past chairs of our Scientific Advisory Board. The prestigious list of expert speakers invited to present their work at this conference includes many current and former Pancreatic Cancer Action Network research grant recipients and members of our Scientific Advisory Board, highlighting our direct role in developing a robust pancreatic cancer research community.

The AACR describes their special conferences as presenting “unique opportunities to interact with the world’s leading experts and discuss the latest findings in rapidly developing areas of cancer research.”

“We are very much looking forward to the opportunity to convene junior and senior investigators in the field, promote collaboration, and brainstorm about new concepts and approaches,” said Lynn Matrisian, PhD, Vice President of Scientific and Medical Affairs at the Pancreatic Cancer Action Network. “We look forward to updating the community about the outcomes of this meeting, and feel confident that ideas sparked at this meeting will help move us towards our goal of doubling the survival rate of pancreatic cancer by 2020.”